Amended Annual Report (10-k/a)
July 13 2021 - 6:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
10-K/A
Amendment
No. 1
(Mark
One)
|
[X]
|
ANNUAL REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
|
|
For the fiscal year
ended December 31, 2020
|
|
|
|
|
|
or
|
|
|
|
|
[ ]
|
TRANSITION REPORT PURSUANT
TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
|
|
For the transition period
from __________ to ______________
|
Commission
file number 000-15327
CytRx
Corporation
(Exact
name of Registrant as specified in its charter)
Delaware
|
|
58-1642740
|
(State or other jurisdiction
of
|
|
(I.R.S. Employer
|
incorporation or organization)
|
|
Identification No.)
|
|
|
|
11726 San Vicente Blvd,
Suite 650,
|
|
|
Los Angeles, California
|
|
90049
|
(Address of principal executive
offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code: (310) 826-5648
Securities
Registered Pursuant to Section 12(b) of the Act:
None
Securities
Registered Pursuant to Section 12(g) of the Act:
Title
of each class
|
|
Name
of exchange on which registered
|
Common
Stock, $0.001 par value per share
|
|
OTC
Market
|
Series
B Junior Participating Preferred Stock Purchase Rights
|
|
OTC
Market
|
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ ] No
[X]
Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [ ]
No [X]
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes [X] No [ ]
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large
accelerated filer [ ]
|
Accelerated
filer [ ]
|
Non-accelerated
filer [X]
|
Smaller
reporting company [X]
|
|
|
|
Emerging
growth company [ ]
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Indicate
by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. [ ]
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [ ] No [X]
Based
on the closing price of the Registrant’s common stock as reported on OTC Market, the aggregate market value of the Registrant’s
common stock held by non-affiliates on June 30, 2020 (the last business day of the Registrant’s most recently completed second
fiscal quarter) was approximately $25.2 million. Shares of common stock held by directors and executive officers and any ten percent
or greater stockholders and their respective affiliates have been excluded from this calculation, because such stockholders may be deemed
to be “affiliates” of the Registrant. This is not necessarily determinative of affiliate status for other purposes. The number
of outstanding shares of the Registrant’s common stock as of March 23, 2021 was 36,780,038 .
Explanatory
Note
CytRx
Corporation (the “Company,” “we” or “us”) is filing this Amendment No. 1 on Form 10-K/A (the
“Amendment”) to its annual report on Form 10-K for the fiscal year ended December 31, 2020, which was originally filed with
the Securities and Exchange Commission (the “Commission”) on March 24, 2021 (the “Original 10-K”).
The
purpose of the Amendment is (1) to file Exhibit 4.3, which was inadvertently omitted from the Original 10-K, (2) to revise
the title page to reflect that our securities are registered pursuant to Section 12(g) of the Securities Exchange Act of 1934 (the “Act”)
rather than Section 12(b) of the Act and (3) to conform the formatting and wording of the cover page to the requirements of the
latest version of Form 10-K. Except as otherwise expressly noted herein, this Amendment does not amend or otherwise update any other
information in our Original 10-K. Accordingly, this Amendment should be read in conjunction with our Original 10-K.
PART
IV
Item
15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a)
The following documents are filed as part of this 10-K:
(1)
Consolidated Financial Statements
No
financial statements are filed with this Amendment No. 1. These items were included as part of the Original 10-K.
(2)
Financial Statement Schedule
None.
Financial statement schedules have not been included because they are not applicable or the information is included in the financial
statements or notes thereto.
(b)
Exhibits
See
Exhibit Index to this Annual Report, which is incorporated herein by reference.
CytRx
Corporation
Form
10-K Exhibit Index
|
|
|
|
Incorporated
By Reference to
|
|
|
Exhibit
Number
|
|
Description
|
|
Form
|
|
Exhibit
|
|
Filing
Date
|
|
Filed
/ Furnished
Herewith
|
2.1
|
|
Agreement and Plan of Merger, dated as of June 6, 2008, among CytRx Corporation, CytRx Merger Subsidiary, Inc., Innovive Pharmaceuticals, Inc., and Steven Kelly
|
|
8-K
|
|
2.1
|
|
6/9/2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.1
|
|
Restated Certificate of Incorporation of CytRx Corporation, as amended
|
|
10-K
|
|
3.1
|
|
3/13/2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.2
|
|
Certificate of Amendment of Restated Certificate of Incorporation
|
|
8-K
|
|
3.1
|
|
5/15/2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.3
|
|
Certificate of Amendment of Restated Certificate of Incorporation
|
|
8-K
|
|
3.1
|
|
11/1/2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.4
|
|
Certificate of Elimination of Designation of Series A Junior Participating Preferred Stock
|
|
8-K
|
|
3.2
|
|
12/19/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.5
|
|
Certificate of Elimination of Series B Convertible Preferred Stock
|
|
8-K
|
|
3.3
|
|
12/19/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.6
|
|
Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock
|
|
8-K
|
|
3.1
|
|
11/17/2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.7
|
|
Amended and Restated By-Laws of CytRx Corporation, effective November 12, 2020
|
|
8-K
|
|
3.2
|
|
11/17/2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.1
|
|
Amended and Restated Rights Agreement, dated as of November 16, 2020, by and between CytRx Corporation and American Stock Transfer & Trust Company, LLC, as rights agent
|
|
8-K
|
|
4.1
|
|
11/17/2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.2
|
|
Warrant, dated as of July 27, 2017, issued by CytRx Corporation to NantCell, Inc.
|
|
8-K
|
|
10.3
|
|
8/1/2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.3
|
|
Description of Securities
|
|
|
|
|
|
|
|
**
|
|
|
|
|
|
|
|
|
|
|
|
10.1*
|
|
CytRx Corporation Amended and Restated 2008 Stock Incentive Plan
|
|
10-K
|
|
10.6
|
|
3/13/2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.1.2*
|
|
Eighth Amendment to Amended and Restated CytRx Corporation 2008 Stock Incentive Plan
|
|
14A
(proxy)
|
|
Annex B
|
|
5/20/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.1.3*
|
|
Form of Non-qualified Stock Option for grants to non-employee directors under Amended and Restated 2008 Stock Incentive Plan.
|
|
10-K
|
|
10.11
|
|
3/11/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.1.4*
|
|
Form of Non-qualified Stock Option for grants to executive officers under Amended and Restated 2008 Stock Incentive Plan.
|
|
10-K
|
|
10.12
|
|
3/11/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.1.5*
|
|
Form of Non-qualified Stock Option for grants to Steven A. Kriegsman and Daniel J. Levitt, M.D., Ph.D., under Amended and Restated 2008 Stock Incentive Plan.
|
|
10-K
|
|
10.13
|
|
3/11/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.1.6*
|
|
Amendment No. 1 to Stock Option Agreements of Daniel J. Levitt, M.D., Ph.D., dated December 31, 2015.
|
|
10-K
|
|
10.14
|
|
3/11/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.1.7*
|
|
Amendment No. 1 to Stock Option Agreements (2000 Long-Term Incentive Plan) of Steven A. Kriegsman, dated March 8, 2016.
|
|
10-K
|
|
10.15
|
|
3/11/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.1.8*
|
|
Amendment No. 1 to Stock Option Agreements (2008 Stock Incentive Plan) of Steven A. Kriegsman, dated March 8, 2016
|
|
10-K
|
|
10.16
|
|
3/11/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.2†
|
|
License Agreement, dated December 7, 2001, by and between CytRx Corporation and Vical Incorporated
|
|
8-K
|
|
99
|
|
12/21/2001
|
|
|
|
|
|
|
Incorporated
By Reference to
|
|
|
Exhibit
Number
|
|
Description
|
|
Form
|
|
Exhibit
|
|
Filing
Date
|
|
Filed
/ Furnished
Herewith
|
10.3
|
|
Office Lease between The Kriegsman Capital Group, LLC and Douglas Emmett Joint Venture, dated April 13, 2000
|
|
10-K
|
|
10.63
|
|
5/14/2004
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.3.1
|
|
Assignment, Assumption and Consent, effective July 1, 2003, by and among CytRx Corporation, The Kriegsman Capital Group, LLC and Douglas Emmett Joint Venture, concerning Office Lease dated April 13, 2000
|
|
10-K
|
|
10.64
|
|
5/14/2004
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.3.2
|
|
Fifth Amendment to Office Lease dated January 13, 2020 by and between CytRx Corporation and Douglas Emmett 1993, LLC
|
|
10-K
|
|
10.3.2
|
|
3/24/2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.4†
|
|
License
Agreement dated April 17, 2006 between Innovive Pharmaceuticals, Inc. and KTB Tumorforschungs GmbH
|
|
10-Q
|
|
10.15
|
|
11/14/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.4.1
|
|
Amendment dated March 14, 2014 to License Agreement between CytRx Corporation and KTB Tumorforschungs GmbH
|
|
8-K
|
|
1.1
|
|
3/17/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.5
|
|
Asset Purchase Agreement dated May 13, 2011 between CytRx Corporation and Orphazyme ApS
|
|
10-Q
|
|
10.1
|
|
8/9/2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.6
|
|
Exclusive License Agreement, dated as of July 27, 2017, by and between CytRx Corporation and NantCell, Inc.
|
|
8-K
|
|
10.1
|
|
8/1/2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.7
|
|
Amended and Restated Employment Agreement, dated March 26, 2019, by and between CytRx Corporation and Steven A. Kriegsman
|
|
10-K
|
|
10.18
|
|
3/29/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.7.1
|
|
First Amendment, dated December 19, 2019, to Amended and Restated Employment Agreement, dated March 26, 2019, by and between CytRx Corporation and Steven A. Kriegsman
|
|
8-K
|
|
10.1
|
|
12/19/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.8
|
|
Employment Agreement, dated January 8, 2021, by and between CytRx Corporation and John Y. Caloz
|
|
10-K
|
|
10.8
|
|
3/24/2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.9
|
|
CytRx Corporation 2019 Stock Incentive Plan
|
|
8-K
|
|
10.1
|
|
11/15/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.1
|
|
Consent of Weinberg & Co
|
|
10-K
|
|
23.1
|
|
3/24/2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.1
|
|
Certification of Chief Executive Officer Pursuant to 15 U.S.C. Section 7241, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
|
|
|
|
|
**
|
|
|
|
|
|
|
|
|
|
|
|
31.2
|
|
Certification of Chief Financial Officer Pursuant to 15 U.S.C. Section 7241, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
|
|
|
|
|
**
|
|
|
|
|
|
|
|
|
|
|
|
32.1
|
|
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
10-K
|
|
32.1
|
|
3/24/2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32.2
|
|
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
10-K
|
|
32.2
|
|
3/24/2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.INS++
|
|
XBRL
Instance Document.
|
|
10-K
|
|
101
|
|
3/24/2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.SCH++
|
|
XBRL Taxonomy Extension Schema Document.
|
|
10-K
|
|
101
|
|
3/24/2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.CAL++
|
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
10-K
|
|
101
|
|
3/24/2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.DEF++
|
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
|
10-K
|
|
101
|
|
3/24/2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.LAB++
|
|
XBRL Taxonomy Extension Label Linkbase Document.
|
|
10-K
|
|
101
|
|
3/24/2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.PRE++
|
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
|
10-K
|
|
101
|
|
3/24/2021
|
|
|
|
*
|
Indicates a management
contract or compensatory plan or arrangement.
|
|
**
|
Filed herewith.
|
|
|
|
|
†
|
Confidential treatment
has been requested or granted for certain portions which have been blanked out in the copy of the exhibit filed with the Securities
and Exchange Commission. The omitted information has been filed separately with the Securities and Exchange Commission.
|
|
++
|
Pursuant to applicable
securities laws and regulations, the Registrant is deemed to have complied with the reporting obligation relating to the submission
of interactive data files in such exhibits and is not subject to liability under any anti-fraud provisions of the federal securities
laws as long as the Registrant has made a good faith attempt to comply with the submission requirements and promptly amends the interactive
data files after becoming aware that the interactive data files fails to comply with the submission requirements. These interactive
data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities
Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and
otherwise are not subject to liability under these sections.
|
Item
16. FORM 10-K SUMMARY
None.
SIGNATURES
In
accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
CYTRX CORPORATION
|
|
|
|
Date: July 12, 2021
|
By:
|
/s/
STEVEN A. KRIEGSMAN
|
|
|
Steven
A. Kriegsman
|
|
|
Chairman and Chief Executive
Officer
|
|
|
(Principal Executive Officer)
|
|
|
|
Date: July 12, 2021
|
By:
|
/s/
JOHN Y. CALOZ
|
|
|
John
Y. Caloz
|
|
|
Chief Financial Officer
|
|
|
(Principal Financial and
Accounting Officer)
|
CytRx (QB) (USOTC:CYTR)
Historical Stock Chart
From Mar 2024 to Apr 2024
CytRx (QB) (USOTC:CYTR)
Historical Stock Chart
From Apr 2023 to Apr 2024